Replies to post #88616 on Anavex Life Sciences Corp (AVXL)

[ExtremelyBullishZig]

Thank you for backing up my claim.

[apostrophe]

"Anavex Receives Notice of Allowance for U.S. Patent Application Related to ANAVEX 2-73

NEW YORK, Aug. 12, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Pat. App. No. 14/205,637 related to ANAVEX 2-73. Upon issuance, the patent will provide intellectual property (IP) protection until at least 2035. ANAVEX2-73 is the subject of an ongoing Phase 2a clinical trial for the treatment of Alzheimer’s disease. [...]"

https://globenewswire.com/news-release/2015/08/12/760035/0/en/Anavex-Receives-Notice-of-Allowance-for-U-S-Patent-Application-Related-to-ANAVEX-2-73.html

Allowance is 99% of the way there. It makes sense to try to hold off issuance until FDA requirements are completed, until commercial production and distribution are imminent, hence the "at least" qualifier. In regard to the many other initial disclosure filings for combo etc. , they provide coverage in that the Anavex claims precede all other potential claims in the relevent areas. For example, although the long term usage of donepezil is dubious, it may still have some usefulness in combo at the onset of treatment, so if that can be patented, they need to try. Otherwise, if it turns out that combo can't, it also means that nobody else can either.